15 completed, 3 active not recruiting, 3 terminated, 1 withdrawn. 12 Phase 2, 11 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 7, Active not recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 1 | 11 | Completed 7, Active not recruiting 2, Terminated 2 |
| Phase 3 | 2 | Completed 2 |
Follow necitumumab: new trials by email Literature Review of necitumumab trials Research Report on necitumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer Necitumumab, Osimertinib, Quality-of-Life Assessment - Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2021-01-29 | 2026-07-17 |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) Osimertinib, Savolitinib, Gefitinib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 247 | 2019-06-25 | 2025-01-30 |
| QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed Aldoxorubicin HCl, ETBX-011, ETBX-021 - Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 4 | 2018-01-09 | 2024-08-05 |
| Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab) - Solid Tumor, Adult | Phase 1 | Completed | Glycotope GmbH | 50 | 2017-11-02 | 2021-07-12 |
| Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer Afatinib, Necitumumab, Laboratory Biomarker Analysis - Non-Small Cell Lung Carcinoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 22 | 2017-07-20 | 2022-04-14 |
| A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Necitumumab, Gemcitabine, Carboplatin - Locally Advanced Squamous Non-Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Eli Lilly and Company | 2016-11-01 | 2019-09-27 | |
| A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer Ramucirumab, Necitumumab, Osimertinib - Non-small Cell Lung Cancer | Phase 1 | Completed | Eli Lilly and Company | 29 | 2016-10-24 | 2024-02-05 |
| Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor Biospecimen Collection, Computed Tomography, Echocardiography Test - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 138 | 2016-05-11 | 2026-07-31 |
| A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC Necitumumab, Nab-Paclitaxel, Carboplatin - Carcinoma, Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | Eli Lilly and Company | 54 | 2015-10-12 | 2020-11-19 |
| A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC Necitumumab, Pembrolizumab - Stage IV Non-Small Cell Lung Cancer | Phase 1 | Completed | Eli Lilly and Company | 71 | 2015-09-04 | 2020-10-05 |
| A Study of LY3023414 and Necitumumab in Squamous Lung Cancer LY3023414, Necitumumab - Non-small Cell Lung Cancer Metastatic | Phase 2 | Terminated | Eli Lilly and Company | 31 | 2015-07-01 | 2020-12-09 |
| A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) Necitumumab, Abemaciclib - Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | Phase 1 | Completed | Eli Lilly and Company | 66 | 2015-06-04 | 2020-07-09 |
| A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) Necitumumab, Gemcitabine, Cisplatin - Squamous Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 192 | 2013-05-07 | 2019-10-25 |
| A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer Necitumumab, Gemcitabine, Cisplatin - Non-small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 61 | 2013-03-01 | 2016-06-27 |
| A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer Necitumumab, Paclitaxel, Carboplatin - Squamous Non Small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 167 | 2013-01-01 | 2019-09-20 |
| A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors Necitumumab - Solid Tumors | Phase 2 | Completed | Eli Lilly and Company | 75 | 2012-08-01 | 2016-07-25 |
| A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin Necitumumab, Gemcitabine, Cisplatin - Malignant Solid Tumor | Phase 2 | Completed | Eli Lilly and Company | 35 | 2012-08-01 | 2019-09-30 |
| First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin Necitumumab, Gemcitabine, Cisplatin - Non Small Cell Lung Cancer | Phase 3 | Completed | Eli Lilly and Company | 1093 | 2010-01-07 | 2025-06-18 |
| Study of IMC-11F8 in Participants With Advanced Solid Tumors IMC-11F8 - Neoplasms | Phase 1 | Completed | Eli Lilly and Company | 15 | 2010-01-01 | 2017-02-03 |
| First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin Pemetrexed, Cisplatin, Necitumumab - Non Small Cell Lung Cancer | Phase 3 | Completed | Eli Lilly and Company | 633 | 2009-11-02 | 2022-01-11 |
Showing 20 of 22. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Lung Neoplasms (3) · Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Lung Diseases (1) · Neoplasm Metastasis (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Eli Lilly and Company (16) · AstraZeneca (1) · Glycotope GmbH (1) · ImmunityBio, Inc. (1) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · Vanderbilt-Ingram Cancer Center (1)
United States (16) · Spain (9) · France (6) · Belgium (5) · Germany (5) · Italy (5) · Japan (4) · Russia (4) · South Korea (4) · Canada (3) · Netherlands (3) · Poland (3) · Romania (3) · Taiwan (3) · United Kingdom (3)
Helena A Yu, MD (1) · Jonathan W Goldman (1) · Jonathan W Riess (1) · Sally York, M.D. (1) · Sebastian Ochsenreither, Dr. med. (1)
PMID 25701171, PMID 26045340, PMID 26980471, PMID 27207107, PMID 29158123, PMID 30797492, PMID 32027845, PMID 33046516, PMID 34389237, PMID 35397434, PMID 39521433, PMID 40466026, PMID 41130408, PMID 41780641, PMID 42361644, PMID 42381014
2009 (2), 2015 (2), 2004 (1), 2016 (1), 2017 (1), 2018 (1), 2023 (1), UM1CA186717 (1)